It was created two years ago as a Bioknostic spinoff, specialized in biotechnology. But it was now when BioClonal, focused on the design of proteins and antibodies for the treatment of diseaseshas inaugurated its new facilities in the Empresarium industrial estate in Zaragoza in which it has invested around one million euros.
The new facilities have a surface area of around 1,000 square meters where BioClonal has its offices, but also the laboratories and other areas to carry out the design and immunization services of monoclonal antibodies for use in human therapy and create solutions that lead to treatments and drugs for diseases such as Alzheimer’s, among others.
The company has developed a advanced technological platform which in turn allows the development of innovative tools for the early diagnosis of pathologies and targeted therapies for neuroinflammatory processes.
The facilities and processes carried out have been explained during the visit by the president of the Government of Aragon, Jorge Azcón, who highlighted the “very important research effort” of this company, which was selected to represent the manufacturing sector. Spanish biotechnology in the Boston Challenge programorganized by Richi Entrepreneurs and ICEX.
The antibody sector has been growing progressively, especially since 2014. Currently, between 10 and 12 monoclonal antibodies have received approval from the FDA and other organizations worldwide for use as therapeutic drugs.
Despite this, the number of monoclonals for specific targets is not growing as quickly, although they are relevant for therapeutic drugs. This is mainly due to technological barriers that BioClonal is expected to be able to overcome with its platform.
#BioClonal #inaugurates #facilities #Zaragoza #design #proteins #antibodies #treat #diseases
